Life Sciences Report

The market for bioelectronic medicine will exceed $60 billion by 2029.

Bioelectronic Medicine 2019-2029

Focus on emerging technologies for electrical neuromodulation, including spinal cord stimulators, deep brain stimulators, vagus nerve stimulators, trigeminal nerve stimulators and more

Brand new for November 2018

 
Bioelectronic medicine, or electroceuticals, is the use of electrical stimulation to treat diseases of the human body in ways that current pharmaceutical interventions cannot. Though the term "bioelectronic medicine" is relatively new, electrical stimulation has been used for the treatment of diseases since the invention of the artificial pacemaker in the early 1900s.
 
From the development of the implantable artificial pacemaker, the field of bioelectronic medicine has expanded into the treatment of many other diseases. This report focuses on emerging areas of electrical neuromodulation, or the application of electrical stimulation to specific nerves within human body. Electrical neuromodulation has been used to treat illnesses such as chronic pain and Parkinson's disease, and can be used to restore function to muscles, as well as the senses of hearing and sight.
 
Electrical neuromodulation began in the 1960s with the development of stimulators for the central nervous system. The spinal cord and areas of the brain were targeted for the treatment of chronic pain and movement disorders respectively. Both fields have remained relatively unchanged in the last 30 years, and thus this report explores the emerging technologies that are disrupting this industry.
 
More recently, there has been increasing interest in developing bioelectronic medicine that modulates the peripheral nervous system. In this area, companies are particularly interested in electrical neuromodulation of the vagus nerve. Leading this effort are SetPoint Medical and Galvani Bioelectronics, two high profile companies which have been backed by industry giants in the medical device, technology, and pharmaceutical industries. Modulation of the vagus nerve promises to treat a myriad of diseases, including diabetes and rheumatoid arthritis.
 
Bioelectronic medicines have enormous opportunities in the treatment of chronic diseases and disorders, especially if they can replace traditional pharmaceutical medicines. Innovators in the field are driving down the size of components and improving electrode technologies to provide greater patient comfort and less invasive implantation procedures. Others are exploring non-invasive devices that can provide electrical neuromodulation through the skin.
 
This report provides an overview of devices for cardiac rhythm management, cochlear implants, and retinal implants, and gives a comprehensive analysis of companies developing electrical neuromodulators of both the central and peripheral nervous systems. Included in this report are devices that stimulate the spinal cord (including dorsal root ganglion), brain, vagus nerve, sacral nerve, tibial nerve, trigeminal nerve, and many others.
 
In this report, the market for bioelectronic medicine is forecast to exceed $60 billion by the year 2029. The 10-year market forecast is broken down into individual markets of cardiac, cochlear, retinal, central nervous system and peripheral nervous system implants.
Analyst access from IDTechEx
All report purchases include up to 30 minutes telephone time with an expert analyst who will help you link key findings in the report to the business issues you're addressing. This needs to be used within three months of purchasing the report.
Further information
If you have any questions about this report, please do not hesitate to contact our report team at research@IDTechEx.com or call one of our sales managers:

Americas: +1 617 577 7890
Europe: +44 1223 812300
Korea: +82 31 263 7890
China: +86 158 5036 8392
Taiwan: +886 (0)9 3999 9792
Rest of Asia: +81 90 1704 1184
Table of Contents
1.EXECUTIVE SUMMARY
1.1.Bioelectronic Medicine
1.2.Major Forms of Bioelectronic Medicine
1.3.The Nervous System
1.4.Bioelectronic Medicine Market Forecast 2019 - 2029
1.5.Bioelectronic Medicine Market Breakdown 2019 vs 2029
1.6.Cardiac Rhythm Management and Heart Failure
1.7.Cardiac Market Forecast 2019 - 2029
1.8.Cochlear and Retinal Implant Market Forecast 2019 - 2029
1.9.Electrical Neuromodulation of the Central Nervous System
1.10.CNS Market Forecast 2019 - 2029
1.11.Pharmaceuticals vs Electroceuticals
1.12.The Reach of Peripheral Nerve Stimulation is Vast
1.13.Electrical Neuromodulation of the Peripheral Nervous System
1.14.Moving to First Line Therapy
1.15.Next Generation Devices
2.INTRODUCTION
2.1.Bioelectronic Medicine: Definition and Scope of Report
2.2.Major Forms of Bioelectronic Medicine
2.3.Initiation, Emergence, and Trends
2.4.The Evolution of Bioelectronic Medicine
2.5.Rise of Bioelectronic Medicine
2.6.Pharmaceuticals vs Electroceuticals
2.7.Bioelectronic Medicine as an Alternative to Opioids
2.8.The Nervous System
2.9.How Neurons Normally Function
2.10.How Neurons Normally Function - The Synaptic Cleft
2.11.Neuromodulation
2.12.Neuroprosthetics Defined
2.13.Re-Engineering Sight and Sound
2.14.Bioelectronic Device Components
2.15.Pulse Generators
2.16.Leads and Electrodes
2.17.Controllers and Chargers
2.18.MR Conditional
2.19.Rechargeable vs Recharge-Free vs No Batteries
2.20.Applications of Bioelectronic Medicine
2.21.Challenges to Next Generation Bioelectronic Medicine
3.MARKET TRENDS
3.1.Key Market Trends
3.2.Key Players: Established Applications
3.3.Abbott Acquires St Jude Medical
3.4.Key Players: Emerging Applications
3.5.GlaxoSmithKline
3.6.Galvani Bioelectronics
3.7.SetPoint Medical
3.8.Research Initiatives Drive Basic and Translational Research
3.9.The BRAIN Initiative
3.10.Stimulating Peripheral Activity to Relieve Conditions
3.11.ElectRx
3.12.Ageing Populations
3.13.The Impact of Sensory Loss
3.14.The Prevalence and Expected Rise of Macular Degeneration
3.15.Back Pain is a Major Cause of Disability
3.16.Challenges from Bench to Bedside
3.17.Regulatory: Invasiveness of the Device
3.18.Regulatory: CE Mark
3.19.New Regulations in the EU
3.20.Regulatory: FDA
3.21.Regulatory: FDA Timeline
3.22.Reimbursement
3.23.Moving to First Line Therapy
4.MARKET FORECAST
4.1.Introduction
4.2.Bioelectronic Medicine Market Forecast 2019 - 2029
4.3.Bioelectronic Medicine Market Breakdown 2019 vs 2029
4.4.Cardiac Market Forecast 2019 - 2029
4.5.Cochlear and Retinal Implant Market Forecast 2019 - 2029
4.6.Cochlear and Retinal Implant Market Breakdown 2019 vs 2029
4.7.CNS Market Forecast 2019 - 2029
4.8.PNS Market Forecast 2019 - 2029
4.9.PNS Market Forecast 2019 - 2029: Discussion
4.10.Ongoing Clinical Trials
5.APPLICATIONS
5.1.Cardiac Rhythm Management and Heart Failure
5.1.1.Introduction
5.1.2.Key Players
5.1.3.Cardiac Market 2013 - 2018
5.1.4.Devices and Indications
5.1.5.Components
5.1.6.Implantation Procedure
5.1.7.Bradycardia and Heart Block
5.1.8.Pacemakers
5.1.9.Leadless Pacemaker
5.1.10.Heart Failure
5.1.11.Cardiac Resynchronization Therapy
5.1.12.Implantable Cardioverter Defibrillators
5.1.13.Extravascular Cardioverter Defibrillator
5.1.14.Key Trends - Cardiac
5.1.15.Drivers and Constraints - Cardiac
5.2.Cochlear Implants
5.2.1.How We Hear Normally
5.2.2.Major Technological Developments in Cochlear Implants
5.2.3.Cochlear Implants
5.2.4.Outline of a Cochlear Implant
5.2.5.Special Considerations for Cochlear Implants
5.2.6.Major Players for Hearing Restoration
5.2.7.Cochlear
5.2.8.Advanced Bionics
5.2.9.MED-EL
5.2.10.Outlook - Cochlear Implants
5.3.Retinal Implants
5.3.1.How We See Normally
5.3.2.How We See with Retinal Degeneration
5.3.3.A Brief History of Vision Restoration
5.3.4.Artificial Retinas
5.3.5.Artificial Retinas - Epiretinal Implants
5.3.6.Artificial Retinas - Subretinal Implants
5.3.7.Intracortical Visual Prosthetics
5.3.8.Special Considerations for Vision
5.3.9.Major Players for Neuroprosthetic Sight Restoration
5.3.10.Second Sight Medical
5.3.11.Pixium Vision
5.3.12.Retina Implant
5.3.13.Outlook - Retinal Implants
5.4.Central Nervous System
5.4.1.Introduction
5.4.2.CNS Players
5.4.3.CNS Market 2013 - 2018
5.4.4.Spinal Cord and Dorsal Root Ganglion Stimulation
5.4.5.Deep Brain Stimulation
5.5.Peripheral Nervous System
5.5.1.Introduction
5.5.2.Players
5.5.3.PNS Market 2013 - 2018
5.5.4.Vagus Nerve Stimulation
5.5.5.Trigeminal Nerve Stimulation
5.5.6.Sacral Nerve Stimulation
5.5.7.Other Nerve Targets
5.5.8.Peripheral Nerve Stimulation for Chronic Pain
6.NEXT GENERATION DEVICES
6.1.Introduction
6.2.An Interdisciplinary Approach is Required
6.3.Visceral Nerve Atlas
6.4.Neural Interfacing Technology
6.5.Closed Loop Systems
6.6.Closed Loop Systems: Requirements
6.7.Outlook - Next Generation Devices
7.ACRONYMS
7.1.List of Acronyms
8.COMPANY PROFILES

Ordering Information

 
 
-Electronic (1-5 users)$5,495.00
-Electronic (6-10 users)$7,995.00
-Electronic and 1 Hardcopy (1-5 users)$5,995.00
-Electronic and 1 Hardcopy (6-10 users)$8,495.00
Click here to enquire about additional licenses.
If you are a reseller/distributor please contact us before ordering.
お問合せ、見積および請求書が必要な方はm.murakoshi@idtechex.com までご連絡ください。

Subscription Enquiry

X

Report Statistics

-Slides254
-Companies11
-Last updateNov 2018
 

Samples

pdf Document Sample pages